Isis Initiates Phase 1 Study Of ISIS-PTP1BRx To Treat Type 2 Diabetes

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B. ISIS-PTP1BRx is designed to increase the body’s sensitivity to the natural hormone insulin, resulting in better glucose control for patients with type 2 diabetes…
Diabetes News From Medical News Today

Responses are currently closed, but you can trackback from your own site.

Comments are closed.

Copyright 2010 DiabetesSigns.org, Inc. All rights reserved. The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments. See the Terms of Service for more information. Privacy Policy

Powered by Yahoo! Answers